Adcock Ingram announced its JSE listing and unbundling from Tiger Brands yesterday in an effort to boost its expansion plans. The pharmaceutical group delisted from the JSE in 1999 and was bought out by Tiger Brands which sought to take advantage of brands such as Panado. However, Tiger saw the company mostly as a cash cow and failed to implement any significant investment, leaving it to trail behind competitors such as Aspen Pharmacare. - Zweli Mokgata
Adcock Ingram announced its JSE listing and unbundling from Tiger Brands yesterday in an effort to boost its expansion plans. The pharmaceutical group delisted from the JSE in 1999 and was bought out by Tiger Brands which sought to take advantage of brands such as Panado. However, Tiger saw the company mostly as a cash cow and failed to implement any significant investment, leaving it to trail behind competitors such as Aspen Pharmacare. - Zweli Mokgata
A chance to grow
Adcock Ingram announced its JSE listing and unbundling from Tiger Brands yesterday in an effort to boost its expansion plans. The pharmaceutical group delisted from the JSE in 1999 and was bought out by Tiger Brands which sought to take advantage of brands such as Panado. However, Tiger saw the company mostly as a cash cow and failed to implement any significant investment, leaving it to trail behind competitors such as Aspen Pharmacare. - Zweli Mokgata
Adcock Ingram announced its JSE listing and unbundling from Tiger Brands yesterday in an effort to boost its expansion plans. The pharmaceutical group delisted from the JSE in 1999 and was bought out by Tiger Brands which sought to take advantage of brands such as Panado. However, Tiger saw the company mostly as a cash cow and failed to implement any significant investment, leaving it to trail behind competitors such as Aspen Pharmacare. - Zweli Mokgata